Enfusion: Revenue Growth Should Start To Accelerate

I wrote about Enfusion (NYSE: ENFN ) previously ( in August ) with a buy rating as management showed promising execution in its effort to move upmarket, and that growth should recover when theI am an individual investor that is now fully focus on managing my own capital that I have saved up over the years. My investing background spreads across a wide spectrum as I believe there are merits to each approach, for instance: Fundamental investing [Bottoms-up etc.], Technical investing [historical charts analysi ...